The FDA approved oral glasdegib (Daurismo, Pfizer) for use with low-dose cytarabine (LDAC) to treat newly diagnosed acute myeloid leukemia (AML) in older adults who may not be able to receive intensive chemotherapy.
NOVEMBER 28, 2018
NOVEMBER 28, 2018
The FDA approved oral glasdegib (Daurismo, Pfizer) for use with low-dose cytarabine (LDAC) to treat newly diagnosed acute myeloid leukemia (AML) in older adults who may not be able to receive intensive chemotherapy.